Search Within

Gary Ulaner

Formats
  1. Journal Article (95)
  2. Meeting Abstract (39)
  3. Miscellaneous (5)
  4. Review (4)
  5. Editorial (2)
  6. Book Whole (1)
  7. Guidelines (1)
Groups
  1. Molecular Imaging and Therapy Service (147)
  2. Radiology, Department of (147)
  3. Department of Medicine (75)
  4. Solid Tumor Oncology Division (60)
  5. GSK Faculty (59)
  6. Epidemiology and Biostatistics (46)

More Groups

People
  1. David Hyman (22)
  2. Christopher Riedl (21)
  3. Maxine Jochelson (21)
  4. Jason Lewis (20)
  5. Maura Dickler (19)
  6. Komal Jhaveri (18)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (2)
  4. 2022 (2)
  5. 2021 (12)
  6. 2020 (21)

More Years

Publications
  1. Journal of Nuclear Medicine (24)
  2. Clinical Nuclear Medicine (23)
  3. Journal of Clinical Oncology (16)
  4. Cancer Research (8)
  5. PET Clinics (7)
  6. European Journal of Nuclear Medicine and Molecular Imaging (6)

More Publications

Publishers
  1. Lippincott Williams & Wilkins (27)
  2. Society of Nuclear Medicine (24)
  3. American Society of Clinical Oncology (16)
  4. Elsevier Inc. (16)
  5. American Association for Cancer Research (12)
  6. Springer (8)

More Publishers

Results (147)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The contribution of microRNAs to the inflammatory and neoplastic characteristics of Erdheim–Chester disease
    Journal Article

    Weissman, R.; Diamond, E. L.; Haroche, J.; Pillar, N.; Shapira, G.; Durham, B. H.; Buthorn, J.; Cohen, F.; Ki, M.; Stemer, G.; more...
    Cancers (2020)

    Fulltext@MSK | Save
  • Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)
    Meeting Abstract

    Campone, M.; Bardia, A.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Pelekanou, V.; Celanovic, M.; Linden, H. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Chi, P.; Qin, L. X.; Kelly, C. M.; D'Angelo, S. P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Movva, S.; Nacev, B.; Crago, A. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Extramedullary myeloma of the uterus on (18)F-FDG PET/CT: A rare manifestation of multiple myeloma
    Miscellaneous

    Causa Andrieu, P. I.; Das, J. P.; Woo, S.; Ryan, R.; Akin, O.; Ulaner, G. A.
    Clinical Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Acute aortic dissection initially suspected on (18)F-FDG PET/CT
    Miscellaneous

    Ulaner, G. A.; Muehlbauer, S.; Goldberg, Z.
    Clinical Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Identification of HER2-positive metastases in patients with HER2-negative primary breast cancer by using HER2-targeted (89)Zr-pertuzumab PET/CT
    Journal Article

    Ulaner, G. A.; Carrasquillo, J. A.; Riedl, C. C.; Yeh, R.; Hatzoglou, V.; Ross, D. S.; Jhaveri, K.; Chandarlapaty, S.; Hyman, D. M.; Zeglis, B. M.; more...
    Radiology (2020)

    Fulltext@MSK | Save
  • Neurologic and oncologic features of Erdheim-Chester disease: A 30-patient series
    Journal Article

    Bhatia, A.; Hatzoglou, V.; Ulaner, G.; Rampal, R.; Hyman, D. M.; Abdel-Wahab, O.; Durham, B. H.; Dogan, A.; Ozkaya, N.; Yabe, M.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Accelerated single cell seeding in relapsed multiple myeloma
    Journal Article

    Landau, H. J.; Yellapantula, V.; Diamond, B. T.; Rustad, E. H.; Maclachlan, K. H.; Gundem, G.; Medina-Martinez, J.; Arango Ossa, J.; Levine, M. F.; Zhou, Y.; more...
    Nature Communications (2020)

    Fulltext@MSK | Save
  • Laboratory-proven asymptomatic SARS-CoV-2 (COVID-19) infection on (18)F-FDG PET/CT
    Miscellaneous

    Krebs, S.; Petkovska, I.; Ho, A. L.; Ulaner, G. A.
    Clinical Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Phase 1/2 dose-escalation and expansion study investigating SAR439859, a potent, oral, selective estrogen receptor degrader, +/- palbociclib in metastatic breast cancer
    Meeting Abstract

    Campone, M.; Bardia, A.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Celanovic, M.; Linden, H. M.
    Cancer Research (2020)

    Fulltext@MSK | Save